Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008;23(2):153-62.
doi: 10.1007/s10654-007-9212-4. Epub 2007 Dec 7.

Use of recommended medications after myocardial infarction in Austria

Wolfgang C Winkelmayer  1 , Anna E Bucsics, Alexandra Schautzer, Peter Wieninger, Michaela Pogantsch; Pharmacoeconomics Advisory Council of the Austrian Sickness Funds
Collaborators, Affiliations

Use of recommended medications after myocardial infarction in Austria

Wolfgang C Winkelmayer et al. Eur J Epidemiol. 2008.

Abstract

Guidelines recommend long-term use of beta-blockers (BB), statins, and angiotensin-converting-enzyme-inhibitors or angiotensin-receptor-blockers (ACEI/ARB) after myocardial infarction (MI), but data on their use after discharge are scarce. From Austrian sickness funds claims, we identified all acute MI patients who were discharged within 30 days and who survived >or=120 days after MI in 2004. We ascertained outpatient use of ACEI/ARBs, BBs, statins, and aspirin from all filled prescriptions between discharge and 120 days post MI. Comorbidities were ascertained from use of indicator drugs during the preceding year. Multivariate logistic regression was used to evaluate the independent determinants of study drug use. We evaluated 4,105 MI patients, whose mean age was 68.8 (+/-13.2) years; 59.5% were men. Within 120 days after MI, 67% filled prescriptions for ACE/ARBs, 74% for BBs, and 67% for statin. While 41% received all these classes and 34% two, 25% of patients received only one or none of these drugs. Older age and presence of severe mental illness were associated with lower use of all drug classes. Diabetics had greater ACEI/ARB use. Fewer BBs were used in patients with obstructive lung disease. Statin use was lower in patients using treatment for congestive heart failure (all P<0.001). We conclude that recommended medications were underused in Austrian MI survivors. Quality indicators should be established and interventions be implemented to ensure maximum secondary prevention after MI.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Proportions of medication use after myocardial infarction
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(99)04021-0', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(99)04021-0'}, {'type': 'PubMed', 'value': '10334252', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10334252/'}]}
    2. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547–57. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJM199809243391301', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejm199809243391301'}, {'type': 'PubMed', 'value': '9744969', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9744969/'}]}
    2. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861–7. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/archinte.163.12.1430', 'is_inner': False, 'url': 'https://doi.org/10.1001/archinte.163.12.1430'}, {'type': 'PubMed', 'value': '12824092', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12824092/'}]}
    2. Burwen DR, Galusha DH, Lewis JM, Bedinger MR, Radford MJ, Krumholz HM, Foody JM. National and state trends in quality of care for acute myocardial infarction between 1994–1995 and 1998–1999: the medicare health care quality improvement program. Arch Intern Med 2003;163:1430–9. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(99)11181-4', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(99)11181-4'}, {'type': 'PubMed', 'value': '10703800', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10703800/'}]}
    2. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, Keil U. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688–700. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(02)09895-1', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(02)09895-1'}, {'type': 'PubMed', 'value': '12241832', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12241832/'}]}
    2. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002;360:752–60. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources